Author

Aitzaz Qaisar

Observed names: A. Qaisar, A., Qaisar

Institutions: Beatson West of Scotland Cancer Centre, University of Glasgow

Observed institutions: NHS Greater Glasgow and Clyde, Beatson West of Scotland Cancer Centre, Gartnavel General Hospital, University of Glasgow

ORCID: 0009-0002-5547-4951

Observed ORCID: 0009-0002-5547-4951

OpenAlex ID: A5079808461

Antimicrobial peptide 99mTc-ubiquicidin 29-41 as human infection-imaging agent: clinical trial.

2005 · Muhammad Saeed Akhtar, Aitzaz Qaisar, et al. · PubMed · 133

A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC ‐D Index

2025 · Mara Persano, Margherita Rimini, et al. · Liver International · 11

Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population

2025 · Federica Lo Prinzi, Francesca Salani, et al. · International Journal of Cancer · 6

The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population

2025 · Margherita Rimini, Lorenzo Fornaro, et al. · JNCI Journal of the National Cancer Institute · 6

Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer

2025 · Gianmarco Leone, Francesco Orlando, et al. · JAMA Oncology · 5

Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real‐world results from a multicenter and multinational study

2025 · Margherita Rimini, Lorenzo Fornaro, et al. · International Journal of Cancer · 4

Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab

2025 · Chiara Pirrone, Umberto Malapelle, et al. · European Journal of Cancer · 3

UK Real-World Evidence of Using Durvalumab Plus Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer via an Early Access Scheme

2025 · Harry Daniels, Mona Hassan, et al. · Cancers · 2

Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and Durvalumab

2026 · Silvia Camera, Lorenzo Fornaro, et al. · Targeted Oncology · 1

Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort study

2026 · H. Vandeputte, A. Casadei-Gardini, et al. · ESMO Gastrointestinal Oncology

240P: Real-world toxicity data for the use of ipilimumab plus nivolumab in malignant mesothelioma across 11 UK centres

2025 · H. McGrath, M. Elgendy, et al. · Journal of Thoracic Oncology

60 First-line Nivolumab/Ipilimumab in patients with unresectable malignant pleural Mesothelioma (MPM): West of Scotland experience

2024 · Aitzaz Qaisar, Mark White, et al. · Lung Cancer

Predictive value of C reactive protein (CRP) in patients with metastatic renal cell carcinoma (mRCC) treated with pembrolizumab (pembro) and axitinib (axi).

2023 · Aitzaz Qaisar, Balaji Venugopal, et al. · Journal of Clinical Oncology

Works count: 14

Citation count: 171

H-index: 5

I10-index: 2